Log in

TSE:EXEExtendicare Stock Price, Forecast & News

C$5.87
+0.16 (+2.80 %)
(As of 06/4/2020 06:55 AM ET)
Add
Compare
Today's Range
C$5.73
Now: C$5.87
C$5.92
50-Day Range
C$5.37
MA: C$5.98
C$6.75
52-Week Range
C$4.90
Now: C$5.87
C$9.60
Volume496,500 shs
Average Volume413,519 shs
Market CapitalizationC$525.43 million
P/E Ratio16.68
Dividend Yield8.41%
BetaN/A
Extendicare Inc. provides care and services for seniors in Canada. The company offers long term care services; retirement living services; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as well as management and consulting services to third-party owners. It also provides third-party liability insurance products in the United States. As of February 28, 2019, it operated 120 senior care and retirement living centers, including 67 owned and 53 managed centers, as well as home health care operations under the Extendicare, Esprit Lifestyle, and ParaMed brands. Extendicare Inc. was founded in 1968 and is based in Markham, Canada.
Read More
Extendicare logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 1.9Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Long-Term Care Facilities
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone905-470-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$1.13 billion
Cash FlowC$1.22 per share
Book ValueC$1.25 per share

Profitability

Miscellaneous

Employees23,000
Market CapC$525.43 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive EXE News and Ratings via Email

Sign-up to receive the latest news and ratings for EXE and its competitors with MarketBeat's FREE daily newsletter.

Extendicare (TSE:EXE) Frequently Asked Questions

How has Extendicare's stock been impacted by COVID-19 (Coronavirus)?

Extendicare's stock was trading at C$6.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EXE shares have decreased by 12.6% and is now trading at C$5.87. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Extendicare?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Extendicare in the last year. There are currently 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Extendicare.

When is Extendicare's next earnings date?

Extendicare is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Extendicare.

How often does Extendicare pay dividends? What is the dividend yield for Extendicare?

Extendicare declared a monthly dividend on Thursday, May 14th. Shareholders of record on Friday, May 29th will be given a dividend of 0.04 per share on Monday, June 15th. This represents a $0.48 annualized dividend and a yield of 8.18%. The ex-dividend date of this dividend is Thursday, May 28th. View Extendicare's dividend history.

What price target have analysts set for EXE?

7 brokers have issued 12-month price objectives for Extendicare's stock. Their forecasts range from C$6.00 to C$8.00. On average, they expect Extendicare's share price to reach C$7.33 in the next year. This suggests a possible upside of 24.9% from the stock's current price. View analysts' price targets for Extendicare.

Has Extendicare been receiving favorable news coverage?

Press coverage about EXE stock has trended negative on Thursday, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Extendicare earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutExtendicare.

Who are some of Extendicare's key competitors?

What other stocks do shareholders of Extendicare own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Extendicare investors own include Inter Pipeline (IPL), Martinrea International (MRE), Medical Facilities (DR), Chorus Aviation (CHR), Pembina Pipeline (PPL), Air Canada (AC), BCE (BCE), Cenovus Energy (CVE), Emera (EMA) and Cominar REIT (CUF.UN).

Who are Extendicare's key executives?

Extendicare's management team includes the following people:
  • Ms. Jillian E. Fountain, VP of Investor Relations
  • Ms. Elaine E. Everson, VP of Corp. Devel.
  • Dr. Michael R. Guerriere, CEO, Pres & Director (Age 54)
  • Mr. David E. Bacon, Sr. VP & CFO
  • Mr. Brandon Leigh Parent, VP, Gen. Counsel & Corp. Sec.

What is Extendicare's stock symbol?

Extendicare trades on the Toronto Stock Exchange (TSX) under the ticker symbol "EXE."

How do I buy shares of Extendicare?

Shares of EXE and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Extendicare's stock price today?

One share of EXE stock can currently be purchased for approximately C$5.87.

How big of a company is Extendicare?

Extendicare has a market capitalization of C$525.43 million and generates C$1.13 billion in revenue each year. Extendicare employs 23,000 workers across the globe.

What is Extendicare's official website?

The official website for Extendicare is www.extendicare.com.

How can I contact Extendicare?

The company can be reached via phone at 905-470-4000.

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.